27440725|t|Jak1 - STAT3 Signals Are Essential Effectors of the USP6 / TRE17 Oncogene in Tumorigenesis
27440725|a|Bone and soft tissue tumors (BSTT) are relatively poorly understood, hampering the development of effective therapies. Here we report a role for the ubiquitin-specific protease 6 (USP6)/ TRE17 oncogene, which is overexpressed upon chromosome translocation in various human tumors, including aneurysmal bone cyst (ABC), and the related benign lesion nodular fasciitis. Ectopic expression of USP6 is known to drive formation of tumors, which recapitulate key features of ABC and nodular fasciitis; however, the identity of USP6's relevant substrates has been obscure. Here we report that the Jak1 - STAT3 signaling pathway serves as an essential effector of USP6 in BSTT formation. We found that USP6 directly deubiquitinated Jak1, leading to its stabilization and activation of STAT3. The tumorigenic potential of USP6 was attenuated significantly by CRISPR -mediated deletion of Jak1 or STAT3, or by administration of a Jak family inhibitor. Analysis of primary clinical samples of nodular fasciitis confirmed the activation of a Jak1 - STAT3 gene signature in vivo Together, our studies highlight Jak1 as the first identified substrate for USP6, and they offer a mechanistic rationale for the clinical investigation of Jak and STAT3 inhibitors as therapeutics for the treatment of bone and soft tissue tumors along with other neoplasms driven by USP6 overexpression. Cancer Res; 76(18); 5337-47. Â©2016 AACR.
27440725	0	4	Jak1	T116,T126	C0169658
27440725	7	12	STAT3	T116,T123	C0253050
27440725	13	20	Signals	T043	C0037083
27440725	25	34	Essential	T080	C0205224
27440725	35	44	Effectors	T116,T123	C0599560
27440725	52	56	USP6	T116,T126	C1175888
27440725	59	73	TRE17 Oncogene	T116,T126	C1175888
27440725	77	90	Tumorigenesis	T191	C0596263
27440725	91	95	Bone	T191	C0005967
27440725	100	118	soft tissue tumors	T191	C0037579
27440725	120	124	BSTT	T191	C0027651
27440725	174	185	development	T169	C1527148
27440725	189	198	effective	T080	C1704419
27440725	199	208	therapies	T061	C0087111
27440725	218	224	report	T170	C0684224
27440725	240	269	ubiquitin-specific protease 6	T116,T126	C1175888
27440725	271	275	USP6	T116,T126	C1175888
27440725	278	292	TRE17 oncogene	T116,T126	C1175888
27440725	303	316	overexpressed	T045	C1514559
27440725	322	346	chromosome translocation	T049	C0040715
27440725	358	363	human	T016	C0086418
27440725	364	370	tumors	T191	C0027651
27440725	382	402	aneurysmal bone cyst	T047	C0152244
27440725	404	407	ABC	T047	C0152244
27440725	426	432	benign	T080	C0205183
27440725	433	439	lesion	T033	C0221198
27440725	440	457	nodular fasciitis	T047	C0410005
27440725	459	477	Ectopic expression	T045	C1512167
27440725	481	485	USP6	T116,T126	C1175888
27440725	504	513	formation	T169	C1522492
27440725	517	523	tumors	T191	C0027651
27440725	544	556	key features	T080	C2348519
27440725	560	563	ABC	T047	C0152244
27440725	568	585	nodular fasciitis	T047	C0410005
27440725	600	608	identity	T078	C0017390
27440725	612	618	USP6's	T116,T126	C1175888
27440725	628	638	substrates	T120	C0178623
27440725	665	671	report	T170	C0684224
27440725	681	685	Jak1	T116,T126	C0169658
27440725	688	693	STAT3	T116,T123	C0253050
27440725	694	711	signaling pathway	T044	C0037080
27440725	725	734	essential	T080	C0205224
27440725	735	743	effector	T116,T123	C0599560
27440725	747	751	USP6	T116,T126	C1175888
27440725	755	759	BSTT	T191	C0027651
27440725	760	769	formation	T169	C1522492
27440725	785	789	USP6	T116,T126	C1175888
27440725	799	814	deubiquitinated	T044	C1157996
27440725	815	819	Jak1	T116,T126	C0169658
27440725	821	828	leading	T169	C1522538
27440725	836	849	stabilization	T033	C0184512
27440725	854	864	activation	T045	C0599177
27440725	868	873	STAT3	T116,T123	C0253050
27440725	879	890	tumorigenic	T191	C0007621
27440725	891	900	potential	T080	C3245505
27440725	904	908	USP6	T116,T126	C1175888
27440725	913	940	attenuated significantly by	T080	C0332161
27440725	941	947	CRISPR	T114	C3658200
27440725	958	966	deletion	T045	C0017260
27440725	970	974	Jak1	T028	C1334290
27440725	978	983	STAT3	T028	C1367307
27440725	991	1005	administration	T169	C1621583
27440725	1011	1021	Jak family	T116,T126	C0597721
27440725	1022	1031	inhibitor	T080	C1999216
27440725	1033	1041	Analysis	T062	C0936012
27440725	1045	1069	primary clinical samples	T077	C2347026
27440725	1073	1090	nodular fasciitis	T047	C0410005
27440725	1091	1100	confirmed	T033	C0750484
27440725	1105	1115	activation	T045	C0599177
27440725	1121	1125	Jak1	T116,T126	C0169658
27440725	1128	1133	STAT3	T116,T123	C0253050
27440725	1134	1148	gene signature	T169	C1708225
27440725	1149	1156	in vivo	T062	C0681829
27440725	1171	1178	studies	T059	C0947630
27440725	1189	1193	Jak1	T116,T126	C0169658
27440725	1218	1227	substrate	T120	C0178623
27440725	1232	1236	USP6	T116,T126	C1175888
27440725	1255	1276	mechanistic rationale	T078	C2699007
27440725	1285	1307	clinical investigation	T058	C1261322
27440725	1311	1314	Jak	T116,T126	C0597721
27440725	1319	1324	STAT3	T116,T123	C0253050
27440725	1325	1335	inhibitors	T080	C1999216
27440725	1339	1351	therapeutics	T169	C0302350
27440725	1360	1369	treatment	T061	C0087111
27440725	1373	1377	bone	T191	C0005967
27440725	1382	1400	soft tissue tumors	T191	C0037579
27440725	1418	1427	neoplasms	T191	C0027651
27440725	1438	1442	USP6	T116,T126	C1175888
27440725	1443	1457	overexpression	T045	C1514559